FFA
HRTX icon

Farther Finance Advisors’s Heron Therapeutics HRTX Stock Holding History

Farther Finance Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75 Buy
175
+22
+14% +$18 ﹤0.01% 5820
2026
Q1 		$123 Buy
153
+101
+194% +$117 ﹤0.01% 5490
2025
Q4 		$68 Buy
+52
New +$64 ﹤0.01% 5330
2024
Q3 		– Sell
-555
Closed -$1.93K – 4057
2024
Q2 		$1.93K Buy
+555
New +$1.71K ﹤0.01% 2809
2023
Q3 		– Sell
-100
Closed -$116 – 2648
2023
Q2 		$116 Buy
+100
New +$178 ﹤0.01% 2419

Other funds holding HRTX

CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
AR
Apeiron RIA Dallas, Texas $390M AUM 22.97% 1-Year Est. Return
DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
TWM
TopTier Wealth Management Muskego, Wisconsin $166M AUM

Farther Finance Advisors's HRTX Position: Q2 2026 in Review

Farther Finance Advisors increased its Heron Therapeutics (HRTX) stake by 14% in Q2 2026, buying an estimated $18 and bringing the position to 175 shares worth $75. The position accounts for ﹤0.01% of the portfolio, ranked #5820.

Farther Finance Advisors first reported a position in HRTX in Q2 2023 and has held it in 5 quarters since. The position peaked at $1.93K in Q2 2024. 20 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Farther Finance Advisors held 175 shares of Heron Therapeutics worth $75 as of Q2 2026.
  • Farther Finance Advisors bought 22 Heron Therapeutics shares in Q2 2026, an estimated $18.
  • Heron Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5820 holding.
  • Farther Finance Advisors first reported a position in Heron Therapeutics in Q2 2023 and has held it in 5 quarters since.
  • Farther Finance Advisors's Heron Therapeutics position peaked at $1.93K in Q2 2024.
  • 20 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.